128 related articles for article (PubMed ID: 35189579)
1. Self-perceived versus physician documented adverse events in patients with multiple sclerosis REGIMS-a pharmacovigilance registry for patients with multiple sclerosis in Germany.
Moeller SN; Simbrich A;
Mult Scler Relat Disord; 2022 Mar; 59():103684. PubMed ID: 35189579
[TBL] [Abstract][Full Text] [Related]
2. Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry.
Simbrich A; Thibaut J; Khil L; Maximov S; Wiendl H; Berger K;
Drug Saf; 2021 Jan; 44(1):7-15. PubMed ID: 33098059
[TBL] [Abstract][Full Text] [Related]
3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
6. Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.
Nicol C; Moulis F; Bondon-Guitton E; Durrieu G; Montastruc JL; Bagheri H
Therapie; 2019 Oct; 74(5):521-525. PubMed ID: 31029402
[TBL] [Abstract][Full Text] [Related]
7. Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial - The problem of generalizability.
Jalusic KO; Ellenberger D; Stahmann A; Berger K;
Mult Scler Relat Disord; 2023 Jan; 69():104422. PubMed ID: 36455503
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
9. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
Meca-Lallana JE; Oreja-Guevara C; Muñoz D; Olascoaga J; Pato A; Ramió-Torrentà L; Meca-Lallana V; Hernández MA; Marzo ME; Álvarez-Cermeño JC; Rodríguez-Antigüedad A; Montalbán X; Fernández O;
PLoS One; 2021; 16(10):e0258437. PubMed ID: 34644366
[TBL] [Abstract][Full Text] [Related]
10. Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).
Palleria C; Iannone L; Leporini C; Citraro R; Manti A; Caminiti M; Gigliotti P; Grembiale RD; L'Andolina M; Muccari G; Naturale MD; Olivo D; Pagano Mariano G; Pellegrini R; Varcasia G; Abdalla K; Russo E; Ursini F; De Sarro G
PLoS One; 2018; 13(10):e0205134. PubMed ID: 30356301
[TBL] [Abstract][Full Text] [Related]
11. Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study.
Castelnovo G; Gerlach O; Freedman MS; Bergmann A; Sinay V; Castillo-Triviño T; Kong G; Koster T; Williams H; Gafson AR; Killestein J
CNS Drugs; 2021 Sep; 35(9):1009-1022. PubMed ID: 34322853
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
13. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
Tourbah A; Papeix C; Tourniaire P; Rerat K; Meite M; Durand B; Lamy F; Chouette I; Mekies C;
Mult Scler Relat Disord; 2020 Nov; 46():102433. PubMed ID: 32862037
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
15. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal.
Herdeiro MT; Ribeiro-Vaz I; Ferreira M; Polónia J; Falcão A; Figueiras A
Drug Saf; 2012 Aug; 35(8):655-65. PubMed ID: 22788235
[TBL] [Abstract][Full Text] [Related]
16. Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy.
Sharma JB; Krishnamurthy MN; Awase A; Joshi A; Patil V; Noronha V; Prabhash K; Gota V
Ther Adv Drug Saf; 2021; 12():2042098621991280. PubMed ID: 33628419
[TBL] [Abstract][Full Text] [Related]
17. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
Iannone LF; Bennardo L; Palleria C; Roberti R; De Sarro C; Naturale MD; Dastoli S; Donato L; Manti A; Valenti G; D'Amico D; D'Attola S; De Francesco AE; Bosco V; Donato Di Paola E; Nisticò SP; Citraro R; Russo E; De Sarro G
PLoS One; 2020; 15(11):e0241575. PubMed ID: 33141869
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
[TBL] [Abstract][Full Text] [Related]
20. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
Antonazzo IC; Poluzzi E; Forcesi E; Riise T; Bjornevik K; Baldin E; Muratori L; De Ponti F; Raschi E
Mult Scler; 2019 Oct; 25(12):1633-1640. PubMed ID: 30230957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
